Triple Negative Breast Cancer (TNBC) | Norton Healthcare

Indication: Triple Negative Breast Cancer (TNBC)

A phase III double-blind randomized study assessing the efficacy of capivasertib + paclitaxel versus placebo + paclitaxel as first-line treatment for patients with histologically confirmed, locally advanced or metastatic triple-negative breast cancer (TNBC)

Sub-indication: Breast Cancer

Drug Study

Principal Investigator: Laila Agrawal, M.D.
Norton Cancer Institute

Sponsor: AstraZeneca

Learn more at ClinicalTrials.gov

Email for more information: Breast-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.